✦ LIBER ✦

Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors

✍ Scribed by Giuseppe Pandini; Thierry Wurch; Barbara Akla; Nathalie Corvaia; Antonino Belfiore; Liliane Goetsch

Book ID: 116429305
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 425 KB
Volume: 43
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.03.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

195 POSTER In vitro and in vivo inhibiti

195 POSTER In vitro and in vivo inhibition of functional responses at insulin-like growth factor-1/insulin hybrid receptors by h7C10, a novel humanized anti-IGF-1R monoclonal antibody

✍ T. Wurch; G. Pandini; B. Akla; N. Corvaia; A. Belfiore; L. Goetsch 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Embryo-fetal developmental toxicity of f

Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys

✍ Christopher J. Bowman; Gary Chmielewski; Satoru Oneda; Deborah Finco; Mary A. Bo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

Anti-insulin-like growth factor 1 recept

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma

✍ Birgit Geoerger; Jean-François Brasme; Estelle Daudigeos-Dubus; Paule Opolon; Co 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 921 KB

A recombinant humanized anti-insulin-lik

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

✍ Liliane Goetsch; Alexandra Gonzalez; Olivier Leger; Alain Beck; Petrus J. Pauwel 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 959 KB

## Abstract Interaction of insulin‐like growth factor receptor I (IGF‐IR) with its ligands has been reported to induce cell proliferation, transformation and blockade of cell apoptotic functions. IGF‐IR is overexpressed on numerous tumor cell types and its blockade could be of importance for anti‐c

A dose finding, safety and pharmacokinet

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

✍ Soria, Jean Charles; Massard, Christophe; Lazar, Vladimir; Ozoux, Marie-Laure; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 358 KB

196 POSTER A phase I trial incorporating

196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer

✍ P.C. Fong; R.L. Molife; J. Spicer; T.A. Yap; S. Settatree; L. Digue; G. Attard; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 71 KB